Cornercap Investment Counsel Inc. Takes $494,000 Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Cornercap Investment Counsel Inc. bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 23,683 shares of the biopharmaceutical company’s stock, valued at approximately $494,000.

Several other hedge funds and other institutional investors have also bought and sold shares of CPRX. Vanguard Group Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 4.9% in the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock worth $175,957,000 after acquiring an additional 390,116 shares during the last quarter. Pacer Advisors Inc. lifted its stake in Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after purchasing an additional 151,495 shares during the last quarter. Boston Partners boosted its position in Catalyst Pharmaceuticals by 1.3% during the fourth quarter. Boston Partners now owns 1,291,868 shares of the biopharmaceutical company’s stock valued at $27,325,000 after buying an additional 16,601 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Catalyst Pharmaceuticals by 6.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,246,925 shares of the biopharmaceutical company’s stock worth $26,023,000 after buying an additional 79,182 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Catalyst Pharmaceuticals by 80.3% in the fourth quarter. JPMorgan Chase & Co. now owns 736,197 shares of the biopharmaceutical company’s stock worth $15,364,000 after buying an additional 327,936 shares during the period. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on CPRX. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Stephens reaffirmed an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Bank of America reissued a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Robert W. Baird boosted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, March 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $32.29.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $24.69 on Friday. The stock has a market cap of $3.00 billion, a PE ratio of 20.92, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. The stock has a fifty day moving average of $22.66 and a 200 day moving average of $21.81. Catalyst Pharmaceuticals, Inc. has a one year low of $14.47 and a one year high of $26.16.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total value of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. The trade was a 25.04 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.